Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; 10 of the 23 sources its claims cite were checked for support.

Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome

Open access

Abstract

Study Question: What is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? Summary Answer: International evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS. What is Known Already: The 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from six continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low to low quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, evidence quality was low and evidence-practice gaps persist. Study Design, Size, Duration: The 2023 International Evidence-based Guideline update reengaged the 2018 network across professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength and diversity and inclusion were considered throughout. Participants/Materials, Setting, Methods: This summary should be read in conjunction with the full Guideline for detailed participants and methods. Governance included a six-continent international advisory and management committee, five guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health and other experts, alongside consumers, project management, evidence synthesis, statisticians and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and five face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across five guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council (NHMRC). Main Results and the Role of Chance: The evidence in the assessment and management of PCOS has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report and analyses (∼6000 pages) underpins 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include: i) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti-Müllerian hormone (AMH) levels as an alternative to ultrasound in adults only; ii) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; iii) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care and shared decision making to improve patient experience, alongside greater research; iv) maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and v) emphasizing evidence-based medical therapy and cheaper and safer fertility management. Limitations, Reasons for Caution: Overall, recommendations are strengthened and evidence is improved, but remain generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided. Wider Implications of the Findings: The 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation programme supports the Guideline with an integrated evaluation program. Study Funding/Competing Interest(s): This effort was primarily funded by the Australian Government via the National Health Medical Research Council (NHMRC) (APP1171592), supported by a partnership with American Society for Reproductive Medicine, Endocrine Society, European Society for Human Reproduction and Embryology, and the European Society for Endocrinology. The Commonwealth Government of Australia also supported Guideline translation through the Medical Research Future Fund (MRFCRI000266). HJT and AM are funded by NHMRC fellowships. JT is funded by a Royal Australasian College of Physicians (RACP) fellowship. Guideline development group members were volunteers. Travel expenses were covered by the sponsoring organizations. Disclosures of interest were strictly managed according to NHMRC policy and are available with the full guideline, technical evidence report, peer review and responses (www.monash.edu/medicine/mchri/pcos). Of named authors HJT, CTT, AD, LM, LR, JBoyle, AM have no conflicts of interest to declare. JL declares grant from Ferring and Merck; consulting fees from Ferring and Titus Health Care; speaker's fees from Ferring; unpaid consultancy for Ferring, Roche Diagnostics and Ansh Labs; and sits on advisory boards for Ferring, Roche Diagnostics, Ansh Labs, and Gedeon Richter. TP declares a grant from Roche; consulting fees from Gedeon Richter and Organon; speaker's fees from Gedeon Richter and Exeltis; travel support from Gedeon Richter and Exeltis; unpaid consultancy for Roche Diagnostics; and sits on advisory boards for Roche Diagnostics. MC declares travels support from Merck; and sits on an advisory board for Merck. JBoivin declares grants from Merck Serono Ltd.; consulting fees from Ferring B.V; speaker's fees from Ferring Arzneimittell GmbH; travel support from Organon; and sits on an advisory board for the Office of Health Economics. RJN has received speaker's fees from Merck and sits on an advisory board for Ferring. AJoham has received speaker's fees from Novo Nordisk and Boehringer Ingelheim. The guideline was peer reviewed by special interest groups across our 39 partner and collaborating organizations, was independently methodologically assessed against AGREEII criteria and was approved by all members of the guideline development groups and by the NHMRC.

Overview

CoChat Summary

TL;DR

The 2023 International Evidence-based Guideline update provides 254 recommendations and practice points for PCOS assessment and management, including 77 evidence-based and 54 consensus recommendations with 123 practice points. It updates diagnosis—including AMH as an alternative to ultrasound in adults only—and emphasizes metabolic, cardiovascular, psychological, lifestyle, and fertility care.

Key findings

  • PCOS prevalence is reported as 10% to 13% globally using Rotterdam criteria; prevalence is broadly similar across world regions but may be higher in South East Asian and Eastern Mediterranean regions.
  • Diagnostic updates include maintaining the 2018 criteria (two of clinical/biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology), with serum AMH now usable instead of ultrasound in adults only; AMH should not be used as a single test or in adolescents, and ultrasound/AMH are not needed when irregular cycles and hyperandrogenism are present.
  • Women with PCOS are recognized as at increased risk of impaired glucose tolerance/type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, endometrial hyperplasia/cancer, and pregnancy complications; depression and anxiety are highly prevalent and screening is recommended; lifestyle management is core, with no single diet or exercise type shown superior.
  • For anovulatory infertility with no other infertility factors, letrozole should be first-line ovulation induction; clomiphene with metformin is an alternative; gonadotrophins or laparoscopic ovarian surgery are second-line; IVF is third-line; metformin in pregnancy has not been shown to prevent gestational diabetes, late miscarriage, hypertension in pregnancy, preeclampsia, or macrosomia/birthweight ≥4000 g.

Methods

  • The update reengaged the 2018 network: 39 professional and consumer organizations covering 71 countries; governance included a six-continent international advisory and management committee, five guideline development groups with 56 members, and paediatric, consumer, and translation committees; 20 meetings and five face-to-face forums over 12 months.
  • Evidence synthesis addressed 58 prioritized clinical questions in the abstract (the Methods section reports fifty-five) involving 52 systematic and 3 narrative reviews; AGREE-II-compliant processes and the GRADE framework were applied across evidence quality, feasibility, acceptability, cost, implementation, and recommendation strength, with diversity and inclusion considered throughout.
  • Recommendations were categorized as evidence-based, consensus, or practice points; a technical evidence report and analyses (~6000 pages) underpins 77 evidence-based and 54 consensus recommendations with 123 practice points, approved by the Australian NHMRC.

Limitations

  • Stated: evidence in PCOS assessment and management has generally improved but remains low to moderate quality; recommendations are strengthened yet still generally low to moderate quality; significantly greater research is needed; regional health system variation was considered and acknowledged with a further adaptation process.
  • Stated: several areas have limited evidence—AMH should not yet be used in adolescents, there are no definitive ultrasound PCOM criteria in adolescents, PCOS-specific evidence is limited for COCPs, anti-androgens, and inositol, and long-term offspring effects of metformin exposure remain unclear.
  • Evident: this article is a summary of the guideline; the full technical report and GRADE profiles are not included, so detailed evidence per recommendation cannot be assessed here, and several recommendations are consensus-based due to insufficient PCOS evidence, with some medications used off-label.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/clinem/dgad463

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Algorithm 1—Diagnostic algorithm for polycystic ovary syndrome (PCOS). © Monash University on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life, 2023. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023, Helena Teede et al. Monash University (monash.edu/medicine/mchri/pcos), 2023, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission re reuse, please contact the rights holder. *Exclusion of other causes = TSH, prolactin, 17-OH progesterone, FSH or if clinically indicated exclude other causes (eg, Cushing's syndrome, adrenal tumours). For hypogonadotrophic hypogonadism, usually due to low body fat or intensive exercise, exclude clinically and with LH and FSH levels. TSH, thyroid stimulating hormone.
Figure 1. Algorithm 1—Diagnostic algorithm for polycystic ovary syndrome (PCOS). © Monash University on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life, 2023. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023, Helena Teede et al. Monash University (monash.edu/medicine/mchri/pcos), 2023, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission re reuse, please contact the rights holder. *Exclusion of other causes = TSH, prolactin, 17-OH progesterone, FSH or if clinically indicated exclude other causes (eg, Cushing's syndrome, adrenal tumours). For hypogonadotrophic hypogonadism, usually due to low body fat or intensive exercise, exclude clinically and with LH and FSH levels. TSH, thyroid stimulating hormone.CC BY-NC · PubMed Central
Figure 2. Algorithm 2—Infertility algorithm for polycystic ovary syndrome (PCOS). © Monash University on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life, 2023. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023, Helena Teede et al. Monash University (monash.edu/medicine/mchri/pcos), 2023, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission re reuse, please contact the rights holder. Central blue pathway follows best practice evidence and is preferred.
Figure 2. Algorithm 2—Infertility algorithm for polycystic ovary syndrome (PCOS). © Monash University on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life, 2023. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023, Helena Teede et al. Monash University (monash.edu/medicine/mchri/pcos), 2023, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission re reuse, please contact the rights holder. Central blue pathway follows best practice evidence and is preferred.CC BY-NC · PubMed Central

Verification

Claims the paper makes

9 Valid · 64 Not valid · 1 Not checked · 61 Own results and interpretations

50 more claims

Create a free account to see all 135 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 68
  • It may state two separate claims as one. 31

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 12 references

Cited by

See all 946

Metadata

Authors
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E.
Affiliations
  • Monash Health (AU)
  • National Health and Medical Research Council Centre for Research Excellence in Women's Health in Reproductive Life , Melbourne, Victoria , Australia
  • University of Pennsylvania (US)
  • Oulu University Hospital (FI)
  • UNSW Sydney (AU)
  • Cardiff University (GB)
  • Pennington Biomedical Research Center (US)
  • Eastern Health (AU)
  • National Health and Medical Research Council (AU)
Corresponding author
Teede, Helena J
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2023-08-15
Volume
108
Issue
10
Pages
2447-2469
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4385799520
Cited by
946
References
12
Citations by year
2026: 375 · 2025: 320 · 2024: 215 · 2023: 36
FWCI
226.69
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Funders
  • National Health Medical Research Council (APP1171592)
  • European Society of Human Reproduction and Embryology
  • European Society for Endocrinology
  • Medical Research Future Fund (MRFCRI000266)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
polycystic ovary syndrome, PCOS diagnosis, PCOS management, clinical guidelines, customer engagement, knowledge-practice gap, diagnostic criteria, reproductive outcomes, insulin resistance, hyperandrogenism, endometrial cancer risk, cardiovascular risk, mental health, quality of life, shared decision-making, patient-centered care, guideline development, AGREE II
MeSH terms
Adult, Australia, Child, Female, Humans, Infertility, Female, Polycystic Ovary Syndrome, Pregnancy, Quality of Life, Risk Factors, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. https://app.cochat.ai/papers/10.1210/clinem/dgad463
The paper
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.